Since ACEs and ARBs share a main mechanism of action, which is to act as renin–angiotensin–aldosterone system (RAAS) antagonists, they inhibit angiogenesis and reduce the induction of cancer growth, which may decrease cancer risk over time [210]. This evidence concerns the gene REN and cancer.